Posted by Michael Wonder on 18 May 2025
MHRA approves guselkumab for Crohn’s disease and ulcerative colitis
16 May 2025 - The MHRA has today approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis.
Clinical studies have shown that guselkumab is also efficacious in treating adults with moderately to severely active Crohn’s disease and ulcerative colitis who have not responded well to other treatments or experienced unacceptable adverse effects.
